drugset
drugset / Trial / NCT01254656

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

NCT01254656 ↗

Phase 2 Terminated 108 enrolled Pfizer ViiV Healthcare · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a study to assess long-term safety and efficacy of lersivirine in patients who have completed 96 weeks of treatment with lersivirine in studies A5271015 and A5271022.

Timeline

Start
2011-02
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 600 mg Oral
Comparator Etravirine Small molecule 200 mg Oral
Subject Lersivirine Small molecule 500 mg Oral
Subject Lersivirine Small molecule 750 mg Oral
Subject Lersivirine Small molecule 1000 mg Oral
Background Darunavir Small molecule 600 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral
Background Tenofovir disoproxil fumarate Small molecule 300 mg Oral
Background emtricitabine Other / unclassified 200 mg Oral

Indications

No indication recorded.